CN108366990B - 合成的鞘脂类分子、药物、它们的合成方法及治疗方法 - Google Patents

合成的鞘脂类分子、药物、它们的合成方法及治疗方法 Download PDF

Info

Publication number
CN108366990B
CN108366990B CN201680068271.8A CN201680068271A CN108366990B CN 108366990 B CN108366990 B CN 108366990B CN 201680068271 A CN201680068271 A CN 201680068271A CN 108366990 B CN108366990 B CN 108366990B
Authority
CN
China
Prior art keywords
compound
tumor
cells
cancer
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680068271.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN108366990A (zh
Inventor
艾梅·埃丁格
斯蒂芬·哈内斯伊恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Montreal
University of California San Diego UCSD
Original Assignee
Universite de Montreal
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Montreal, University of California San Diego UCSD filed Critical Universite de Montreal
Publication of CN108366990A publication Critical patent/CN108366990A/zh
Application granted granted Critical
Publication of CN108366990B publication Critical patent/CN108366990B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680068271.8A 2015-09-24 2016-09-26 合成的鞘脂类分子、药物、它们的合成方法及治疗方法 Expired - Fee Related CN108366990B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562232377P 2015-09-24 2015-09-24
US62/232,377 2015-09-24
PCT/US2016/053815 WO2017053990A1 (en) 2015-09-24 2016-09-26 Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment

Publications (2)

Publication Number Publication Date
CN108366990A CN108366990A (zh) 2018-08-03
CN108366990B true CN108366990B (zh) 2021-09-03

Family

ID=58387539

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680068271.8A Expired - Fee Related CN108366990B (zh) 2015-09-24 2016-09-26 合成的鞘脂类分子、药物、它们的合成方法及治疗方法

Country Status (7)

Country Link
US (3) US10995068B2 (enExample)
EP (1) EP3352753A4 (enExample)
JP (1) JP6853539B2 (enExample)
CN (1) CN108366990B (enExample)
CA (1) CA2999177A1 (enExample)
MX (1) MX394367B (enExample)
WO (1) WO2017053990A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11999693B2 (en) 2015-09-24 2024-06-04 The Regents Of The University Of California Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3022176B8 (en) 2013-07-15 2019-12-25 The Regents of the University of California Azacyclic constrained analogs of fty720
MA50532A (fr) * 2017-11-03 2020-09-09 Univ Virginia Patent Foundation Compositions et méthodes pour le traitement de cancers
CA3103805A1 (en) * 2018-06-14 2019-12-19 The Regents Of The University Of California Synthetic cytotoxic molecules, drugs, methods of their synthesis and methods of treatment
WO2021062168A1 (en) * 2019-09-25 2021-04-01 The Regents Of The University Of California Synthetic sphingolipid inspired molecules with heteroaromatic appendages, methods of their synthesis and methods of treatment
US20220409617A1 (en) * 2019-11-13 2022-12-29 The Regents Of The University Of California Drug Formulations and Methods of Treatment for Metabolic Disorders
TWI885039B (zh) 2020-01-13 2025-06-01 美商邊際分析公司 經取代吡唑并嘧啶及其用途
CN116617221B (zh) * 2022-02-11 2025-06-17 复旦大学 Trpml1特异性小分子激动剂ml-sa1在制药中的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009053481A1 (en) * 2007-10-25 2009-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for modulating nk and t cell trafficking
US8309768B2 (en) * 2010-11-29 2012-11-13 The Ohio State University Research Foundation FTY720-derived anticancer agents
WO2015009731A2 (en) * 2013-07-15 2015-01-22 The Regents Of The University Of California Azacyclic constrained analogs of fty720
US9115054B2 (en) * 2013-02-21 2015-08-25 Bristol-Myers Squibb Company Tetrahydronaphthalenyl compounds useful as sipi agonists

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US3931155A (en) 1973-04-25 1976-01-06 Richardson-Merrell Inc. Process for preparing 2-azacycloalkylmethyl ketones
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
EP0366685B1 (en) 1987-06-24 1994-10-19 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US6005087A (en) 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5859221A (en) 1990-01-11 1999-01-12 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5457191A (en) 1990-01-11 1995-10-10 Isis Pharmaceuticals, Inc. 3-deazapurines
JPH0874B2 (ja) 1990-07-27 1996-01-10 アイシス・ファーマシューティカルス・インコーポレーテッド 遺伝子発現を検出および変調するヌクレアーゼ耐性、ピリミジン修飾オリゴヌクレオチド
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5948903A (en) 1991-01-11 1999-09-07 Isis Pharmaceuticals, Inc. Synthesis of 3-deazapurines
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
AU3222793A (en) 1991-11-26 1993-06-28 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
USRE44779E1 (en) 1997-03-07 2014-02-25 Santaris Pharma A/S Bicyclonucleoside and oligonucleotide analogues
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
JP4236812B2 (ja) 1997-09-12 2009-03-11 エクシコン エ／エス オリゴヌクレオチド類似体
US7053207B2 (en) 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
US20030158403A1 (en) 2001-07-03 2003-08-21 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
US20030175906A1 (en) 2001-07-03 2003-09-18 Muthiah Manoharan Nuclease resistant chimeric oligonucleotides
AU2003291755A1 (en) 2002-11-05 2004-06-07 Isis Pharmaceuticals, Inc. Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
WO2004041889A2 (en) 2002-11-05 2004-05-21 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
EP1661905B9 (en) 2003-08-28 2012-12-19 IMANISHI, Takeshi Novel artificial nucleic acids of n-o bond crosslinkage type
CA2538252C (en) 2003-09-18 2014-02-25 Isis Pharmaceuticals, Inc. 4'-thionucleosides and oligomeric compounds
US7638637B2 (en) 2003-11-03 2009-12-29 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
US20050256056A1 (en) 2003-12-05 2005-11-17 The Regents Of The University Of California Office Of Technology Transfer University Of California Peptide inhibitors of HIV
US20070258970A1 (en) 2003-12-09 2007-11-08 Robert Blumenthal Methods for Inhibiting Hiv and Other Viral Infections by Modulating Ceramide Metabolism
WO2005122379A2 (en) 2004-05-27 2005-12-22 The Regents Of The University Of California Alpha-4 beta-1 integrin ligands for imaging and therapy
MX2007001661A (es) 2004-08-13 2007-04-23 Praecis Pharm Inc Metodos y composiciones para modular la actividad del receptor de esfingosina -1 fosfato (sip).
WO2007052578A1 (ja) 2005-10-31 2007-05-10 Toray Fine Chemicals Co., Ltd. ベンジルオキシピロリジン誘導体の製造方法および光学活性ベンジルオキシピロリジン誘導体塩酸塩粉体の製造法
WO2007090071A2 (en) 2006-01-27 2007-08-09 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
US7569686B1 (en) 2006-01-27 2009-08-04 Isis Pharmaceuticals, Inc. Compounds and methods for synthesis of bicyclic nucleic acid analogs
AU2007249349B2 (en) 2006-05-11 2012-03-08 Isis Pharmaceuticals, Inc. 5'-Modified bicyclic nucleic acid analogs
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
WO2007143081A2 (en) 2006-06-02 2007-12-13 The Ohio State University Research Foundation Therapeutic agents for the treatment of lymphoid malignancies
US7968733B2 (en) 2006-06-06 2011-06-28 Gifu University Pyrrolidine analogue for preventing neurogenic pain and method for production thereof
EP2046766A1 (en) 2006-08-01 2009-04-15 Praecis Pharmaceuticals Incorporated Agonists of the sphingosine- 1- phosphate receptor (slp)
WO2008023258A1 (en) 2006-08-23 2008-02-28 Pfizer Products Inc. Piperidine derivatives
BRPI0720478A2 (pt) * 2006-12-21 2014-01-14 Abbott Laboratoires Compostos agonistas e antagonistas do receptor esfingosina-1-fosfato
WO2008097819A2 (en) 2007-02-05 2008-08-14 Smithkline Beecham Corporation Chemical compounds
WO2008101157A1 (en) 2007-02-15 2008-08-21 Isis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
CA2688321A1 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en) 2007-06-08 2016-02-08 Isis Pharmaceuticals Inc Carbocyclic bicyclic nukleinsyreanaloge
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
KR101654007B1 (ko) 2007-08-15 2016-09-05 아이오니스 파마수티컬즈, 인코포레이티드 테트라하이드로피란 핵산 유사체
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
WO2009100320A2 (en) 2008-02-07 2009-08-13 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
WO2009106599A2 (en) 2008-02-29 2009-09-03 Novartis Ag Substituted piperidines as therapeutic compounds
GB0811451D0 (en) 2008-06-20 2008-07-30 Syngenta Participations Ag Novel microbiocides
EA022952B1 (ru) 2008-07-23 2016-03-31 Тамара Александровна ВИТКАЛОВА Способ лечения вирусных гепатитов b и c
DK2356129T3 (da) 2008-09-24 2013-05-13 Isis Pharmaceuticals Inc Substituerede alpha-L-bicykliske nukleosider
US9012421B2 (en) 2009-08-06 2015-04-21 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
US9102938B2 (en) 2010-04-01 2015-08-11 Alnylam Pharmaceuticals, Inc. 2′ and 5′ modified monomers and oligonucleotides
US10913767B2 (en) 2010-04-22 2021-02-09 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
FR2968556B1 (fr) 2010-12-13 2013-12-27 Centre Nat Rech Scient Inhibiteurs des infections a vih et leurs utilisations
WO2014118556A2 (en) 2013-01-31 2014-08-07 Research Foundation Of The City University Of New York Selective inhibitors and allosteric activators of sphingosine kinase
DK2992098T3 (da) 2013-05-01 2019-06-17 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
US10119136B2 (en) 2014-01-09 2018-11-06 Alnylam Pharmaceuticals, Inc. RNAi agents modified at the 4′-C position
US20180078561A1 (en) 2015-03-31 2018-03-22 Lam Therapeutics, Inc. Active metabolites of apilimod and uses thereof
EP3313819A1 (en) 2015-06-23 2018-05-02 Case Western Reserve University Compositions and methods for treating cancer
CA2999177A1 (en) 2015-09-24 2017-03-30 The Regents Of The University Of California Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment
CA3103805A1 (en) 2018-06-14 2019-12-19 The Regents Of The University Of California Synthetic cytotoxic molecules, drugs, methods of their synthesis and methods of treatment
WO2021062168A1 (en) 2019-09-25 2021-04-01 The Regents Of The University Of California Synthetic sphingolipid inspired molecules with heteroaromatic appendages, methods of their synthesis and methods of treatment
US20220409617A1 (en) 2019-11-13 2022-12-29 The Regents Of The University Of California Drug Formulations and Methods of Treatment for Metabolic Disorders
US20240277740A1 (en) 2020-05-16 2024-08-22 Viratides, Llc Treatment of known and unknown viral infection with lipid agents
WO2022094615A1 (en) 2020-10-29 2022-05-05 The Regents Of The University Of California Compounds and methods for increased antisense activity
US20240066006A1 (en) 2020-12-17 2024-02-29 The Regents Of The University Of California Antiviral Compounds and Applications Thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009053481A1 (en) * 2007-10-25 2009-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for modulating nk and t cell trafficking
US8309768B2 (en) * 2010-11-29 2012-11-13 The Ohio State University Research Foundation FTY720-derived anticancer agents
US9115054B2 (en) * 2013-02-21 2015-08-25 Bristol-Myers Squibb Company Tetrahydronaphthalenyl compounds useful as sipi agonists
WO2015009731A2 (en) * 2013-07-15 2015-01-22 The Regents Of The University Of California Azacyclic constrained analogs of fty720

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Rebecca Fransson等.Design, synthesis, and antileukemic activity of stereochemically defined constrained analogues of TFY720 (GILENYA).《ACS medicinal Chemistry letters》.2013,第4卷969-973. *
Stephen Hanessia等.constrained azacyclic analogues of the immunomodulatory agent FTY720 as molecular probes for sphingosine 1-phosphate receptors.《Bioorganic & Medicinal Chemistry Letters》.2006,第17卷491-494. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11999693B2 (en) 2015-09-24 2024-06-04 The Regents Of The University Of California Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment

Also Published As

Publication number Publication date
MX394367B (es) 2025-03-24
EP3352753A4 (en) 2019-03-13
EP3352753A1 (en) 2018-08-01
JP6853539B2 (ja) 2021-03-31
US10995068B2 (en) 2021-05-04
US20230122855A1 (en) 2023-04-20
US11999693B2 (en) 2024-06-04
MX2018003685A (es) 2018-08-15
JP2018534256A (ja) 2018-11-22
US11479530B2 (en) 2022-10-25
US20210261504A1 (en) 2021-08-26
CA2999177A1 (en) 2017-03-30
HK1259078A1 (zh) 2019-11-22
US20180265464A1 (en) 2018-09-20
CN108366990A (zh) 2018-08-03
WO2017053990A1 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
CN108366990B (zh) 合成的鞘脂类分子、药物、它们的合成方法及治疗方法
US12310968B2 (en) Chiral diaryl macrocycles and uses thereof
JP4171061B2 (ja) マレイミド誘導体、医薬組成物、および癌の治療のためのその使用
KR102396717B1 (ko) Ｊａｋ 및 ｐｉ3ｋ 억제제 조합에 의한 ｂ-세포 악성종양의 치료
US9498467B2 (en) Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
JP6509386B2 (ja) ｍＴＯＲ経路関連疾患を治療するための化合物
KR20110132446A (ko) 키나아제 단백질 결합 억제제
EP3265093A1 (en) Tricyclic kinase inhibitors of melk and methods of use
US8716307B2 (en) Combination antineoplastic therapy
US9469625B2 (en) Organic compounds
WO2024163609A1 (en) Compositions for treating cancer
WO2021025148A1 (ja) 抗ｃｃｒ４抗体抵抗性のがんの治療剤
HK1259078B (zh) 合成的鞘脂類分子、藥物、它們的合成方法及治療方法
JP2021531349A (ja) Ｃｄｋインヒビター及びその使用
US9821008B2 (en) Inhibitors of ERCC1-XPF and methods of using the same
TW202412809A (zh) 包含標靶療法的抗癌組合
US11426371B2 (en) Compositions and methods for treating cancer
US20230097801A1 (en) Methods of increasing cell phagocytosis
WO2025230871A1 (en) Compounds, compositions, methods of use, and methods for preparing compounds
WO2019079848A1 (en) METHOD OF TREATING ACUTE MYELOID LEUKEMIA
WO2020219718A1 (en) Small molecule autophagy inducers for the treatment of cancer and neurodegenerative diseases

Legal Events

Date Code Title Description
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1259078

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210903

CF01 Termination of patent right due to non-payment of annual fee